“Existing antimicrobial solutions for medical devices have not met critical needs,” said Shaun Rothwell, EVŌQ Nano CEO. “By incorporating EVQ-218 into various phases of the manufacturing process, the next generation of medical devices has the potential to be equipped with antimicrobial protection to safeguard against infections and complications.” 

HAIs affect over 1 million hospital patients annually,1 leading to significant morbidity, mortality, and approximately $10 billion in yearly healthcare costs.2Extensive lab testing on catheters, luers, fittings, and coatings utilizing EVQ-218 shows strong antimicrobial protection with a >4-log reduction (99.99%) against leading pathogens implicated in HAIs.3 Importantly, the integration of EVQ-218 preserves the original materials’ mechanical and functional properties, ensuring finished products perform as engineered.3 

Novel Mechanism of Action 

EVQ-218 is the first stable, nonemissive, pure silver nanoparticle, opening opportunity for widespread therapeutic use.4 Unlike conventional nanosilvers that often trigger antimicrobial resistance (AMR) by rupturing bacterial cell walls, EVQ-218 employs a novel mechanism of action that kills bacteria from the inside.4 

• EVQ-218 stops bacterial growth by sequestering sulfur. 

• The sequestration of sulfur inhibits metabolic activity within the bacterial cell without compromising cell structures or lysing the cell wall. This avoids activation of bacterial mutations that contribute to antimicrobial resistance. 
• In contrast, nanoparticles with silver ions rupture cell walls, triggering activation of resistance pathways.